SHIRE, NEW RIVER PHARMA GET APPROVABLE LETTER FROM FDA FOR NRP104

Shire plc said Friday that its collaborative partner New River Pharmaceuticals Inc. received an approvable letter from the U.S. Food and Drug Administration for NRP104 for the treatment of pediatric Attention-Deficit/Hyperactivity Disorder.

Trading Markets (http://www.tradingmarkets.com/.site/news/BREAKING%20NEWS/445863/)